These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 22320227)

  • 1. GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer.
    Miyake T; Nakayama T; Naoi Y; Yamamoto N; Otani Y; Kim SJ; Shimazu K; Shimomura A; Maruyama N; Tamaki Y; Noguchi S
    Cancer Sci; 2012 May; 103(5):913-20. PubMed ID: 22320227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of GSTP1 methylation with aggressive phenotype in ER-positive breast cancer.
    Miyake T; Nakayama T; Kagara N; Yamamoto N; Nakamura Y; Otani Y; Uji K; Naoi Y; Shimoda M; Maruyama N; Shimomura A; Shimazu K; Kim SJ; Noguchi S
    Anticancer Res; 2013 Dec; 33(12):5617-23. PubMed ID: 24324107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 14-3-3σ expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers.
    Nakamura Y; Oshima K; Naoi Y; Nakayama T; Kim SJ; Shimazu K; Shimomura A; Maruyama N; Tamaki Y; Noguchi S
    Breast Cancer Res Treat; 2012 Jul; 134(1):229-36. PubMed ID: 22315133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
    Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
    Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.
    Fountzilas G; Dafni U; Bobos M; Batistatou A; Kotoula V; Trihia H; Malamou-Mitsi V; Miliaras S; Chrisafi S; Papadopoulos S; Sotiropoulou M; Filippidis T; Gogas H; Koletsa T; Bafaloukos D; Televantou D; Kalogeras KT; Pectasides D; Skarlos DV; Koutras A; Dimopoulos MA
    PLoS One; 2012; 7(6):e37946. PubMed ID: 22679488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
    Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
    Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC.
    Imanishi S; Naoi Y; Shimazu K; Shimoda M; Kagara N; Tanei T; Miyake T; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2019 Apr; 174(3):627-637. PubMed ID: 30607631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer.
    Ohara AM; Naoi Y; Shimazu K; Kagara N; Shimoda M; Tanei T; Miyake T; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2019 Feb; 173(3):533-543. PubMed ID: 30361874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab.
    Kurozumi S; Inoue K; Takei H; Matsumoto H; Kurosumi M; Horiguchi J; Takeyoshi I; Oyama T
    BMC Cancer; 2015 Sep; 15():622. PubMed ID: 26345461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers.
    Naoi Y; Kishi K; Tanei T; Tsunashima R; Tominaga N; Baba Y; Kim SJ; Taguchi T; Tamaki Y; Noguchi S
    Cancer; 2011 Aug; 117(16):3682-90. PubMed ID: 21305539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological analysis of GATA3-positive breast cancers with special reference to response to neoadjuvant chemotherapy.
    Tominaga N; Naoi Y; Shimazu K; Nakayama T; Maruyama N; Shimomura A; Kim SJ; Tamaki Y; Noguchi S
    Ann Oncol; 2012 Dec; 23(12):3051-3057. PubMed ID: 22767585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers.
    Arai T; Miyoshi Y; Kim SJ; Akazawa K; Maruyama N; Taguchi T; Tamaki Y; Noguchi S
    Eur J Surg Oncol; 2008 Jul; 34(7):734-8. PubMed ID: 17764884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers.
    Kim SJ; Nakayama S; Shimazu K; Tamaki Y; Akazawa K; Tsukamoto F; Torikoshi Y; Matsushima T; Shibayama M; Ishihara H; Noguchi S
    Ann Oncol; 2012 Apr; 23(4):891-7. PubMed ID: 21821547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas.
    Rønneberg JA; Tost J; Solvang HK; Alnaes GI; Johansen FE; Brendeford EM; Yakhini Z; Gut IG; Lønning PE; Børresen-Dale AL; Gabrielsen OS; Kristensen VN
    Cancer Res; 2008 Jul; 68(14):5562-71. PubMed ID: 18632608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China.
    Lv M; Li B; Li Y; Mao X; Yao F; Jin F
    Asian Pac J Cancer Prev; 2011; 12(9):2411-7. PubMed ID: 22296393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
    Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
    Lips EH; Mulder L; de Ronde JJ; Mandjes IA; Vincent A; Vrancken Peeters MT; Nederlof PM; Wesseling J; Rodenhuis S
    Breast Cancer Res Treat; 2012 Feb; 131(3):827-36. PubMed ID: 21472434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.
    Ignatiadis M; Zardavas D; Lemort M; Wilke C; Vanderbeeken MC; D'Hondt V; De Azambuja E; Gombos A; Lebrun F; Dal Lago L; Bustin F; Maetens M; Ameye L; Veys I; Michiels S; Paesmans M; Larsimont D; Sotiriou C; Nogaret JM; Piccart M; Awada A
    PLoS One; 2016; 11(7):e0154009. PubMed ID: 27454930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
    Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.